Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Endocrine Tumors

Interventions

DRUG: lanreotide (Autogel formulation)
DRUG: Placebo

Sponsor

Ipsen